A venture capital view of challenges, opportunities, and innovation in biomedical research.
Small biotech companies have been an important source of innovation, pipelines, and new products for the pharmaceutical industry, and are primarily financed by venture capital (VC). The significant changes happening within the VC industry have broad implications for these small companies. This includes a shift to financing later-stage programs with increasing interest in orphan or specialty indications. Nontraditional sources of capital and innovative risk-sharing structures can enable early-stage companies.
New Leaf Venture Partners, New York, New York, USA. Liam@nlvpartners.com
L T
LT
Ratcliffe
D035843:Biomedical Research / Q000191:economics*; D001709:Biotechnology / Q000191:economics*; D002202:Capital Financing / Q000191:economics*; D003405:Creativity; D004345:Drug Industry / Q000191:economics*